

COLISUIN-CL

Authorised

- Escherichia coli, fimbrial adhesin F4ab
- Escherichia coli, fimbrial adhesin F4ac
- Escherichia coli, fimbrial adhesin F5
- Escherichia coli, fimbrial adhesin F6
- Escherichia coli, LT toxoid
- Clostridium perfringens, type C, beta1 toxoid
- Clostridium novyi, type B, alpha toxoid

Product identification

Medicine name:

COLISUIN-CL

Active substance:

Escherichia coli, fimbrial adhesin F4ab

Escherichia coli, fimbrial adhesin F4ac

Escherichia coli, fimbrial adhesin F5

Escherichia coli, fimbrial adhesin F6

Escherichia coli, LT toxoid

Clostridium perfringens, type C, beta1 toxoid

Clostridium novyi, type B, alpha toxoid

Target species:

Pig (young female)

Pig (sow)

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Escherichia coli, fimbrial adhesin F4ab

80.00 percentage protection / 1.00 Dose

Escherichia coli, fimbrial adhesin F4ac

80.00 percentage protection / 1.00 Dose

Escherichia coli, fimbrial adhesin F5

80.00 percentage protection / 1.00 Dose

Escherichia coli, fimbrial adhesin F6

80.00 percentage protection / 1.00 Dose

Escherichia coli, LT toxoid

80.00 percentage protection / 1.00 Dose

Clostridium perfringens, type C, beta1 toxoid

10.00 international unit(s) / 1.00 Dose

Clostridium novyi, type B, alpha toxoid

3.50 international unit(s) / 1.00 Dose

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:**Intramuscular use:**

-

Pig (young female)

- Meat and offal. 0 day

-

Pig (sow)

- Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI09AB08

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Spain

Package description:

Available only in [Spanish](#)

Available only in [Spanish](#)

Available only in [Spanish](#)

Available only in [Spanish](#)

Available only in [Spanish](#)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Laboratorios Hipra S.A.

Marketing authorisation date:

22/11/1991

Manufacturing sites for batch release:

Laboratorios Hipra S.A.

Responsible authority:

Spanish Agency For Medicines And Medical Devices

Authorisation number:

2551 ESP

Date of authorisation status change:

4/06/2012

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.